top of page
11 juil. 2024
Theranexus announced regulatory alignment with the FDA and EMA on efficacy endpoints for Batten-1 and optimized its upcoming Phase III trial—focused on visual acuity in younger patients—while securing new financing to prepare for its launch.
Lyon, France, Jul 11, 2024 – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its cash position as of 30 June 2024, presents a progress report on Batten-1 and opens a new equity line.
Download Theranexus press release
bottom of page